Economic evaluation of sunitinib versus pazopanib and best supportive care for the treatment of metastatic renal cell carcinoma in Chile: cost-effectiveness analysis and a mixed treatment comparison

References

• Ljungberg B, Bensalah K, Canfield S, et al. EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol. 2015;67(5):913–924.
   PubMed Web of Science ®Google Scholar
• Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet. 2017;373(9669):1119–1132.
   Google Scholar
• WHO. Globocan 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. (Ed.^(Eds) (2012). 2012.
   Google Scholar
• Pischon T, Lahmann PH, Boeing H, et al. Body size and risk of renal cell carcinoma in the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer. 2006;118(3):728–738.
   PubMed Web of Science ®Google Scholar
• Weikert S, Boeing H, Pischon T, et al. Blood pressure and risk of renal cell carcinoma in the European prospective investigation into cancer and nutrition. Am J Epidemiol. 2008;167(4):438–446.
   PubMed Web of Science ®Google Scholar
• Waalkes S, Merseburger AS, Kramer MW, et al. Obesity is associated with improved survival in patients with organ-confined clear-cell kidney cancer. Cancer Causes Control. 2010;21(11):1905–1910.
   PubMed Web of Science ®Google Scholar
• Kovacs G, Akhtar M, Beckwith BJ, et al. The Heidelberg classification of renal cell tumours. (Ed.^(Eds) England; 1997. p. 131–133.
   Google Scholar
• Jonasch E, Gao J, Rathmell WK. Renal cell carcinoma. BMJ. 2014;349:g4797.
   PubMedGoogle Scholar
• Pérez Fentes DA, Blanco Parra M, Toucedo Caamaño V, et al. Carcinoma renal metastásico de localización atípica: revisión de la literatura. (Ed.^(Eds). scieloes, 2005:621–630.
   Google Scholar
• Patel PH, Chaganti RSK, Motzer RJ. Targeted therapy for metastatic renal cell carcinoma. Br J Cancer. 2006;94(5):614–619.
   PubMed Web of Science ®Google Scholar
• Janowitz T, Welsh SJ, Zaki K, et al. Adjuvant therapy in renal cell carcinoma—past, present, and future(). Semin Oncol. 2013;40(4):482–491.
   PubMed Web of Science ®Google Scholar
• Fyfe G, Fisher RI, Rosenberg SA, et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1995;13(3):688–696.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115–124.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J clin oncol. 2009;27(22):3584–3590.
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28(6):1061–1068.
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Hawkins RE, Wagstaff J, et al. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. Eur J Cancer. 2013;49(6):1287–1296.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma. N Engl J Med. 2013;369(8):722–731.
   PubMed Web of Science ®Google Scholar
• Nice. Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma. (Ed.^(Eds). 2009.
   Google Scholar
• Wu B, Dong B, Xu Y, et al. Economic evaluation of first-line treatments for metastatic renal cell carcinoma: a cost-effectiveness analysis in a health resource–limited setting. PLoS ONE. 2012;7(3):e32530–e32530.
   PubMed Web of Science ®Google Scholar
• Minsal. Guia metodologica para la evaluacion economica de ntervenciones en salud en Chile. (Ed.^(Eds). 2013.
   Google Scholar
• Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356(22):2271–2281.
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM, et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol. 2009;27(20):3312–3318.
   PubMed Web of Science ®Google Scholar
• Collett D. Modelling Survival Data in Medical Research, Third Edition (Chapman and Hall/CRC, New York, 2015).
   Google Scholar
• Bcentral. Indicadores Diarios. (Ed.^(Eds). 2014.
   Google Scholar
• Minsal. Estudio verificación del costo esperado individual promedio por beneficiario del conjunto priorizado de problemas de salud con garantías explicitas 2012. Santiago; 2013. (Ed.^(Eds).
   Google Scholar
• Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Suppl 3):iii49–56.
   PubMed Web of Science ®Google Scholar
• Cella D, Cappelleri JC, Bushmakin A, et al. Quality of life predicts progression-free survival in patients with metastatic renal cell carcinoma treated with sunitinib versus interferon alfa. J Oncol Pract. 2009;5(2):66–70.
   PubMedGoogle Scholar
• Isp. Ficha de Producto: sunitinib. (Ed.^(Eds). 2006.
   Google Scholar
• Isp. Ficha de Producto: pazopanib. (Ed.^(Eds). 2013.
   Google Scholar
• Motzer RJ, Escudier B, Tomczak P, et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol. 2013;14(6):552–562.
   PubMed Web of Science ®Google Scholar
• Jonsson L, Sandin R, Ekman M, et al. Analyzing overall survival in randomized controlled trials with crossover and implications for economic evaluation. Value Health. 2014;17(6):707–713.
   PubMed Web of Science ®Google Scholar
• Ishak KJ, Proskorovsky I, Korytowsky B, et al. Methods for adjusting for bias due to crossover in oncology trials. PharmacoEconomics. 2014;32(6):533–546.
   PubMed Web of Science ®Google Scholar
• Amdahl J, Diaz J, Sharma A, et al. Cost-effectiveness of pazopanib versus sunitinib for metastatic renal cell carcinoma in the United Kingdom. PloS one. 2017;12(6):e0175920–e0175920.
   PubMed Web of Science ®Google Scholar
• Amdahl J, Diaz J, Park J, et al. Cost-effectiveness of pazopanib compared with sunitinib in metastatic renal cell carcinoma in Canada. Curr Oncol. 2016;23(4):e340–e354.
   PubMed Web of Science ®Google Scholar
• Capri S, Porta C, Delea TE. Cost-effectiveness of pazopanib versus sunitinib as first-line treatment for locally advanced or metastatic renal cell carcinoma from an Italian national health service perspective. Clin Ther. 2017;39(3):567–580.e562.
   PubMed Web of Science ®Google Scholar
• Delea TE, Amdahl J, Diaz J, et al. Cost-effectiveness of pazopanib versus sunitinib for renal cancer in the United States. J Manag Care Spec Pharm. 2015;21(1):46–54.
   PubMed Web of Science ®Google Scholar
• Nazha S, Tanguay S, Kapoor A, et al. Cost-utility of sunitinib versus pazopanib in metastatic renal cell carcinoma in Canada using real-world evidence. Clin Drug Investig. 2018;38(12):1155–1165.
   PubMed Web of Science ®Google Scholar
• Benedict A, Ramaswamy K, Sandin R. Cost-effectiveness of pazopanib versus sunitinib for renal cancer in the United States. (Ed.^(Eds). United States, 2015:834–840.
   Google Scholar
• Decisiones Informadas en Medicamentos (DIME). Proyecto DIME. (Ed.^(Eds)) (DIME, Bogota).
   Google Scholar
• Vrdoljak E, Torday L, Szczylik C, et al. Pharmacoeconomic and clinical implications of sequential therapy for metastatic renal cell carcinoma patients in central and Eastern Europe. Expert Opin Pharmacother. 2016;17(1):93–104.
   PubMed Web of Science ®Google Scholar
• Chabot I, Rocchi A. How do cost-effectiveness analyses inform reimbursement decisions for oncology medicines in Canada? The example of sunitinib for first-line treatment of metastatic renal cell carcinoma. Value Health. 2010;13(6):837–845.
   PubMed Web of Science ®Google Scholar
• NICE. Appraising life-extending, end of life treatments. National institute for Health and Clinical Excellence. (Ed.^(Eds).
   Google Scholar